Precautions for Vaccinating Immunocompromised Individuals

Vaccination serves critical purposes in public health, including disease prevention, immunotherapy for conditions like cancer, and efforts to eradicate diseases such as smallpox. It also controls disease transmission by achieving high vaccination rates and protecting vulnerable individuals who cannot be vaccinated. These efforts contribute significantly to global health by reducing illness, saving lives, and fostering healthier communities. 

Immunosuppressed individuals face unique challenges regarding vaccination compared to immunocompetent individuals. Due to their compromised immune systems, they may not respond as effectively to vaccines and are at higher risk for vaccine-preventable diseases.

Individuals with immunological challenges can generally be categorized into two main groups: the immunosuppressed and the immunocompromised. Immunosuppressed individuals have intentionally suppressed immune systems, often due to medications like corticosteroids or chemotherapy, or following organ transplantation. On the other hand, immunocompromised individuals have weakened immune systems due to conditions such as HIV/AIDS, genetic disorders affecting immune function, or certain cancers.

The decision to vaccinate immunosuppressed individuals requires careful consideration of their specific medical condition, the type of vaccine, potential risks, and benefits. Consulting with a healthcare provider specializing in immunocompromised conditions is crucial to determine the appropriateness and timing of vaccinations for these individuals.

A vaccine is a biological substance(antigen) that stimulates the immune system by introducing a weakened or inactive pathogen to the body, training the immune system to recognize and fight the disease in the future. They are basically divided into two types: inactivated and live attenuated. Inactivated vaccines are made from microorganisms (viruses, bacteria, etc.) that have been killed by physical or chemical methods, rendering them unable to cause disease.

Immunocompromised as well as immunocompetent individuals residing with immunocompromised patients can safely receive inactivated vaccines. Inactivated vaccines do not contain live pathogens and thus do not pose a threat of causing illness in immunocompromised individuals. This precaution ensures that they minimize the risk of transmitting vaccine-preventable diseases to vulnerable individuals. 

Live attenuated vaccines are made from disease-causing viruses (Wild type) or bacteria that have been weakened in a controlled environment. Live attenuated vaccines replicate in the host but do not cause severe disease like the wild-type organism. They stimulate immunity similarly to natural infections and, therefore, can cause mild symptoms similar to the natural disease. This poses a risk for immunocompromised individuals whose weakened immune systems may struggle to control even weakened pathogens. In such Individuals, even the attenuated antigens ( bacteria or viruses) can replicate and produce symptoms due to their weak immune conditions. 

For instance, in cases of persistent infections such as tuberculosis, administration of the BCG vaccine can result in complications such as localized lymphadenitis or even disseminated infections. Another issue involves the potential contamination of vaccines produced in tissue cultures; if these cultures are contaminated, vaccines may harbour other viruses such as retroviruses, as observed in historical instances involving the measles vaccine.

Similarly, due to safety considerations, live attenuated vaccines (LAVs) are typically avoided during pregnancy to prevent any potential risks to the developing fetus. These precautions are crucial in ensuring vaccines are safe and effective for all individuals, especially those with compromised immune systems or during sensitive periods like pregnancy.

Vaccination recommendations for immunocompromised individuals depend on their specific health conditions and medical guidance. Adjustments to vaccination schedules may be necessary to ensure optimal protection without compromising health. Generally, live vaccines should be administered at least four weeks before starting immunosuppressive therapy and avoided within two weeks before initiation. Inactivated vaccines should ideally be given at least two weeks before immunosuppression. Additionally, immunocompetent individuals who reside with immunocompromised persons should seek advice from healthcare professionals before receiving vaccinations. 

Therefore, individuals with compromised immune systems should be mindful of these guidelines before undergoing any vaccinations.

Antiviral Drug Resistance: A Global Problem

 RNA viruses, renowned for their high mutation rates, undergo rapid evolution. Consequently, genotypes harbouring mutations conferring drug resistance can emerge swiftly. A virus strain is deemed 'resistant' to a drug if it can replicate in the body despite the presence of the drug at concentrations that inhibit replication of 'sensitive' strains. Drug-resistant virus isolates typically exhibit gene mutations encoding the proteins the drug targets. Most mutations leading to drug resistance in HIV-1 involve changes in amino acids. However, some mutations can also involve deletions or insertions of genetic material. In the HIV-1 virus, mutations in the reverse transcriptase gene that make it resistant to nucleoside analogues (such as AZT) occur in different specific codons compared to mutations that confer resistance to non-nucleoside inhibitors (like nevirapine). This difference is because these two classes of drugs target distinct regions within the reverse transcriptase enzyme. This specificity in mutation locations highlights how different drugs can influence HIV-1's genetic makeup differently, affecting its ability to resist treatment.

Clinical challenges arise when drug-resistant virus strains develop in patients undergoing treatment and when these resistant strains are transmitted to others. When drug-resistant HIV strains emerge during treatment, patients may switch to alternative medications. Initially, AZT was widely used for HIV treatment but resistance quickly developed. Similar challenges arose with other single-drug therapies. The current standard for treating HIV infection involves highly active antiretroviral therapy (HAART), which combines different classes of drugs like reverse transcriptase inhibitors and protease inhibitors.

Monitoring the effectiveness of HIV treatment involves measuring HIV RNA levels in the blood. HAART typically leads to a rapid reduction in HIV RNA within the first 10 days, followed by a slower decline over weeks. In some patients, HIV RNA stabilizes at low levels (5-50 copies/ml), while in others, it drops to less than 5 copies/ml over time.

HAART also reduces HIV levels in the seminal fluid of men and the genital secretions of women. While it doesn't eradicate HIV from the body, the virus persists in latent forms in macrophages, memory CD4 T cells, and possibly in immune-privileged sites like the brain and testes. Despite this persistence, HAART has significantly lowered AIDS-related mortality in developed countries. Additionally, treating HIV-positive women has substantially decreased mother-to-child transmission risks.

Overall, HAART represents a pivotal advancement in managing HIV infection, offering optimism through effective suppression of the virus and improved quality of life for patients.

HIV as the emerging infectious Viral disease

 “Infections that have newly appeared in a population or have existed previously but are rapidly increasing in incidence or geographic range” is termed as Emerging infections (EIs). In 1981, a new disease — acquired immune deficiency syndrome (AIDS)was first recognized. The emergence of HIV raised few questions, firstly the zoonotic source of HIV and its inter and intra species transmission.
Simian immunodeficiency virus (SIV)may have transmitted to humans in at least four separate occasions, identified by individual HIV-1 lineages called groups (M, N, O, P). The most important was the M group of HIV-1, main cause of human infections. HIV-1 is most closely related to SIVcpz, the SIV strain infecting two subpopulations of chimpanzees. Different segments of the SIVcpz genome, are closely related to genome segments of two SIVs of African monkeys, red-capped monkeys and Cercopithecus monkeys.

It is assumed that chimpanzees, regularly kills monkeys, were infected during consumption of their prey; and this infection may have led to a recombination event producing SIVcpz, which was derived from parts of the genomes of the two acquired monkey viruses. Further transmission from Chimpanzee to humans may have occurred during butchering of non-human primates mainly in rural Africa.

During the period from 1930 to 1980 the virus remained as a rare and unrecognized infection in residents of jungle villages in West Africa during this time, reuse of unsterilized needles occurred, a frequent practice during the period of colonial rule, could have helped to spread the virus. 

 

In 1980, the virus began to spread more rapidly. Accelerated spread began in the region centered on Kinshasa (previously Leopoldville) in the Democratic Republic of the Congo (previously the Belgian Congo, then Zaire) and Brazzaville, just across the Congo River in Congo. Transmission was enhanced by the chaos in postcolonial Zaire.
During the period 1985–2004, HIV infection spread widely in Africa. And the prevalence of infection among adults aged 15–49years reached levels higher than 30%. 

The rapid spread was driven by many factors ,such as a high frequency of concurrent sexual contacts in some segments of the population and the hidden nature of sexual networks., the long asymptomatic incubation period during which infected individuals able to transmit the virus were sexually active, the spread along commercial routes of travel within Africa; the failure of health systems to publicize the risks and the under utilization of condoms and other measures to reduce transmission the slow introduction of antiviral treatment after it became available in the northern countries about 1996.

With the spread of HIV in Africa, the M group of HIV-1 evolved into nine different subtypes (A–D, F–H, J, K), based on sequence diversity. Subtype C is most frequent in southern Africa, and subtypes A and D are most frequent in eastern Africa. During the 1980s, HIV spreaded globally, although prevalence rates lower than in some African countries. Subtype B is dominant in the western hemisphere and Europe, while subtype C is most frequent in India and some other Asian countries. Although the global incidence of HIV has fallen slightly since 2010, there are still more than two million new infections each year.